Product

Quamatel

1 form: powder. In force in Georgia: 1 of 1 (human register).

Forms and doses1 of 1 in force in Georgia

Form	Dose	Frequency	Georgia
Powder	No label dose in the reference yet	-	Georgia Yes, human In force until 22 Jul 2030 Human (Ministry of Health, RAMA) № რ-043674 GE MoH exact human register Verified on: 22 Oct 2026
Details: pack, label wording, sources, registration Quamatel, Powder Kvamatel 20 mg, powder for solution for injection, human medicine vetman assessment vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient. Dog Short-term hospital IV acid suppression when oral therapy is impossible and acid-related gastroduodenal erosion/ulcer or reflux oesophagitis is suspected or confirmed; not routine antiemesis or nonspecific prophylaxis 6.4/10 Situational / acceptable vetman assessment Quamatel Kvamatel 20 mg, powder for solution for injection, human medicine Assessed clinical scopeDog · Short-term hospital IV acid suppression when oral therapy is impossible and acid-related gastroduodenal erosion/ulcer or reflux oesophagitis is suspected or confirmed; not routine antiemesis or nonspecific prophylaxis · Intravenous Care settingVeterinary hospital use with diagnosis, exact reconstitution, slow administration or infusion, renal review, objective response monitoring and early oral/PPI strategy reassessment vetman score 6.4/10 Situational / acceptable Evidence confidence: Medium Georgia: Yes, human · № რ-043674 · Verified on 22 Oct 2026 Off-label use A transparent, accurately reconstituted hospital IV option with direct canine acid-suppression evidence, but not a routine antiemetic or a first-choice sustained acid suppressant. The direct evidence is physiologic, regimen-dependent and not an exact-product healing trial. Regulatory and scientific credibility6.5/10 The exact 20 mg vial, 5 ml solvent, 4 mg/ml reconstituted concentration, holder and IV-only human label are traceable in current GE and Lithuanian records. Veterinary use is off-label and no exact veterinary dossier exists. Clinical efficacy6.0/10 Randomised healthy-dog IV pH studies show significant short-term acid suppression; a high-dose CRI met human-derived healing pH targets, while intermittent dosing did not. No diseased-dog healing, bleeding, quality-of-life or exact-product outcome trial exists. Safety and tolerability6.5/10 Human exact-label safety and veterinary class experience are substantial, but exact-product dog repeated-dose, diseased-subgroup and reproductive data are absent. Renal accumulation, hypersensitivity, infusion handling and route-related events require review. Clinical practicality7.0/10 The supplied solvent creates a known 4 mg/ml solution suitable for monitored IV measurement, but use requires reconstitution, hospital administration, slow injection or infusion, asepsis, compatibility review and immediate microbiological use. Exact-product SC administration is unsupported. Full-course cost-effectiveness- Exact current Georgian course price and availability were not verified; duration and intermittent-versus-CRI resource use are indication-dependent, so cost is excluded. Important safety and use flags This is a human medicine. Every dog/cat use is off-label and requires an individual veterinary benefit-risk and dose decision. Exact-product veterinary pregnancy, lactation, neonatal and long-term repeated-dose safety are not established. Use only for a specific acid-related erosion, ulcer or reflux rationale when oral therapy is unsuitable. Do not use as a routine antiemetic or automatic cover for gastritis, pancreatitis, renal disease, hepatic disease, corticosteroids or NSAIDs. Twice-daily proton-pump inhibitor treatment generally provides stronger sustained acid suppression. Reassess early whether famotidine is the right strategy. Do not stack famotidine with a PPI empirically; controlled evidence does not show an ulcer-healing advantage and the combination may reduce PPI effectiveness. Intermittent famotidine loses acid-suppressive effect with continued exposure. If treatment continues, reassess diagnosis, pH/healing objective, response and transition strategy rather than escalating blindly. The exact human label is IV-only. Generic clinical SC famotidine exposure does not make SC an authorised or exact-product-supported route. In cats, the reassuring haemolysis study used slow IV administration over five minutes. It supports route safety, not efficacy or rapid bolus administration. Reconstitute the 20 mg vial exactly with the supplied 5 ml solvent to obtain 4 mg/ml. Verify clarity, compatibility, asepsis, injection/infusion rate and immediate microbiological use. Famotidine is substantially renally cleared. Review renal function, accumulation and interval/dose adjustment; also reassess hepatic disease and interacting absorption-sensitive medicines. Contraindicated after hypersensitivity to famotidine, another H2-receptor antagonist or any exact-product excipient. Assessment sources Quamatel injection market audit2026 VVKT Quamatel injection record2026 Quamatel injection product info2023 ACVIM GI-protectant consensus2018 Canine intermittent IV famotidine2005 Canine famotidine CRI2019 Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised. Cat Short-term hospital IV acid suppression when oral therapy is impossible and acid-related gastroduodenal erosion/ulcer or reflux oesophagitis is suspected or confirmed; not routine antiemesis or nonspecific prophylaxis 6.0/10 Situational / acceptable vetman assessment Quamatel Kvamatel 20 mg, powder for solution for injection, human medicine Assessed clinical scopeCat · Short-term hospital IV acid suppression when oral therapy is impossible and acid-related gastroduodenal erosion/ulcer or reflux oesophagitis is suspected or confirmed; not routine antiemesis or nonspecific prophylaxis · Intravenous Care settingVeterinary hospital use with diagnosis, exact reconstitution, slow administration or infusion, renal review, objective response monitoring and early oral/PPI strategy reassessment vetman score 6.0/10 Situational / acceptable Evidence confidence: Medium Georgia: Yes, human · № რ-043674 · Verified on 22 Oct 2026 Off-label use A transparent hospital IV formulation with reassuring slow-IV feline safety data, but injectable feline efficacy remains indirect and PPIs are generally stronger. Use only for a specific acid-related indication when oral therapy is unsuitable. Regulatory and scientific credibility6.5/10 The exact 20 mg vial, 5 ml solvent, 4 mg/ml reconstituted concentration, holder and IV-only human label are traceable in current GE and Lithuanian records. Veterinary use is off-label and no exact veterinary dossier exists. Clinical efficacy4.0/10 Cats have controlled oral pH evidence showing short-term effect inferior to omeprazole and route-specific IV safety exposure, but no feline injectable pH-efficacy or clinical-healing trial. Efficacy of this exact IV product is therefore indirect. Safety and tolerability7.0/10 In 142 hospitalised cats, slow IV famotidine was not associated with haemolysis or a greater PCV decline than SC or control exposure, directly addressing a common concern. This retrospective study does not establish all uncommon, repeated-dose, reproductive or exact-product risks. Clinical practicality7.0/10 The supplied solvent creates a known 4 mg/ml solution suitable for monitored IV measurement, but use requires reconstitution, hospital administration, slow injection or infusion, asepsis, compatibility review and immediate microbiological use. Exact-product SC administration is unsupported. Full-course cost-effectiveness- Exact current Georgian course price and availability were not verified; duration and intermittent-versus-CRI resource use are indication-dependent, so cost is excluded. Important safety and use flags This is a human medicine. Every dog/cat use is off-label and requires an individual veterinary benefit-risk and dose decision. Exact-product veterinary pregnancy, lactation, neonatal and long-term repeated-dose safety are not established. Use only for a specific acid-related erosion, ulcer or reflux rationale when oral therapy is unsuitable. Do not use as a routine antiemetic or automatic cover for gastritis, pancreatitis, renal disease, hepatic disease, corticosteroids or NSAIDs. Twice-daily proton-pump inhibitor treatment generally provides stronger sustained acid suppression. Reassess early whether famotidine is the right strategy. Do not stack famotidine with a PPI empirically; controlled evidence does not show an ulcer-healing advantage and the combination may reduce PPI effectiveness. Intermittent famotidine loses acid-suppressive effect with continued exposure. If treatment continues, reassess diagnosis, pH/healing objective, response and transition strategy rather than escalating blindly. The exact human label is IV-only. Generic clinical SC famotidine exposure does not make SC an authorised or exact-product-supported route. In cats, the reassuring haemolysis study used slow IV administration over five minutes. It supports route safety, not efficacy or rapid bolus administration. Reconstitute the 20 mg vial exactly with the supplied 5 ml solvent to obtain 4 mg/ml. Verify clarity, compatibility, asepsis, injection/infusion rate and immediate microbiological use. Famotidine is substantially renally cleared. Review renal function, accumulation and interval/dose adjustment; also reassess hepatic disease and interacting absorption-sensitive medicines. Contraindicated after hypersensitivity to famotidine, another H2-receptor antagonist or any exact-product excipient. Assessment sources Quamatel injection market audit2026 VVKT Quamatel injection record2026 Quamatel injection product info2023 ACVIM GI-protectant consensus2018 Hospitalised-cat IV famotidine safety2008 Feline famotidine pH crossover2015 Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised. Composition / strength Famotidine20 mg Formulation Type Powder Administration route Intravenous Manufacturer Gedeon Richter Plc. · Hungary Registration Georgia Yes, human In force until 22 Jul 2030 Human (Ministry of Health, RAMA) № რ-043674 GE MoH exact human register Verified on: 22 Oct 2026 EU Yes, human № LT/1/94/1030/003 Lithuanian VVKT exact product record Verified on: 22 Oct 2026 UK Not confirmed MHRA exact brand/holder search Verified on: 22 Oct 2026 US Not confirmed Drugs@FDA exact brand/holder search Verified on: 22 Oct 2026 Controlled in Georgia No Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n. matsne.gov.ge Verified on: 16 Oct 2026 Information not fully verified Exact human label: 20 mg/vial; reconstitution with the supplied 5 ml solvent gives 4 mg/ml; IV only, slow injection or infusion in hospital, with oral transition when feasible. Veterinary intermittent and CRI regimens have different evidence and must not be collapsed into one unrestricted calculator.

Famotidine: No dose supported by a publicly verifiable source yet

Known Contraindications

Warning
Do not use acid-suppressant drugs as antiemetics. Vomiting can be the primary sign of gastritis in dogs and cats, but acid suppression does not treat nausea or vomiting itself.

Sources: ACVIM
Warning
H2-receptor antagonists are eliminated through a combination of renal excretion and hepatic metabolism. Accumulation is expected when both organs are impaired; no specific dose-reduction schedule is provided.

Sources: ACVIM
Warning
In hepatic impairment, account for reduced elimination through one of the two principal clearance pathways; see the corresponding renal-impairment warning.

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 23 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Quamatel

Forms and doses1 of 1 in force in Georgia

Quamatel, Powder

Known Contraindications

Related products

Same therapeutic group 41

All of this shows in vetman as you prescribe